ReviewBone2017
Sclerostin expression and functions beyond the osteocyte.
Review in Bone, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.Frontiers in endocrinology · 2023Pooled it
- Higher Plasma Sclerostin and Lower Wnt Signaling Gene Expression in White Adipose Tissue of Prediabetic South Asian Men Compared with White Caucasian Men.Diabetes & metabolism journal · 2020Trial
- Osteoglycin and Sclerostin Imbalance in Hypophosphatasia: Bone-Derived Markers of Mineralization and Systemic Involvement.International journal of molecular sciences · 2026Article
- The role and therapeutic potential of vitamins in fracture healing.Nutrition journal · 2026Review
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- Association Between Sclerostin and Sarcopenia-Related Functional Decline in Older Women.Diagnostics (Basel, Switzerland) · 2026Article
- Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures.Endocrine · 2025Observational
- Sclerostin antibody promotes alveolar bone regeneration after tooth extraction.Biomolecules & biomedicine · 2025Article
- Partial cementocyte ablation does not reduce cellular cementum apposition in a mouse model of molar super-eruption.Bone reports · 2025Article
- Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.Osteoporosis and sarcopenia · 2025Review
- Bone-formation-related markers in osteonecrosis of the jaws and their correlation with radiographic findings.Oral and maxillofacial surgery · 2025Article
- Palm Tocotrienol Preserves Trabecular Osteocyte Indices and Modulates the Expression of Osteocyte Markers in Ovariectomized Rats.Biomedicines · 2025Article
- Impact of elevated sclerostin levels on bone resorption : unravelling structural changes and mineral metabolism disruption.Bone & joint research · 2025Article
- Effect of High Glucose and Carboxymethyl-Lysine on Osteocyte Gene Expression.American journal of molecular biology · 2025Article
- Low Bone Turnover, Mineralization Impairment, and Cortical Alterations in Patients with Axial Spondyloarthritis: A Histomorphometric Study.Calcified tissue international · 2025Article
- Disparate effects of sclerostin deletion on alveolar bone and cellular cementum in mice.Journal of periodontology · 2025Article
- Osteokines in Nonalcoholic Fatty Liver Disease.Current obesity reports · 2024Review
- Activation of Wnt signaling in human fracture callus and nonunion tissues.Bone reports · 2024Article
- Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm.Cardiovascular diabetology · 2024Article
- Both enantiomers of β-aminoisobutyric acid BAIBA regulate Fgf23 via MRGPRD receptor by activating distinct signaling pathways in osteocytes.Cell reports · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Sclerostin, the product of the SOST gene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes to regulate bone formation. While it is often considered an osteocyte-specific protein, SOST expression has been reported in numerous other cell types, including hypertrophic chondrocytes and cementocytes. Of interest, SOST/sclerostin expression is altered in certain pathogenic conditions, including osteoarthritis and rheumatic joint disease, and it is unclear whether sclerostin plays a protective role or whether sclerostin may mediate disease pathogenesis. Therefore, as anti-sclerostin antibodies are being developed for the treatment of osteoporosis, it is important to understand the functions of sclerostin beyond the regulation of bone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.